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Persistent metabolic changes 
in HIV-infected patients during 
the first year of combination 
antiretroviral therapy
N. Chantal Peltenburg1,8, Johannes C. Schoeman  2, Jun Hou3, Fernando Mora2, 
Amy C. Harms  2, Selwyn H. Lowe4,5, Jörgen Bierau6, Jaap A. Bakker  7, Annelies Verbon1,8, 
Thomas Hankemeier2 & Andre Boonstra3
The HIV-human metabolic relationship is a complex interaction convoluted even more by antiretroviral 
therapy (cART) and comorbidities. The ability of cART to undo the HIV induced metabolic dysregulation 
is unclear and under-investigated. Using targeted metabolomics and multiplex immune biomarker 
analysis, we characterized plasma samples obtained from 18 untreated HIV-1-infected adult 
patients and compared these to a non-HIV infected (n = 23) control population. The biogenic amine 
perturbations during an untreated HIV infection implicated altered tryptophan- nitrogen- and muscle 
metabolism. Furthermore, the lipid profiles of untreated patients were also significantly altered 
compared to controls. In untreated HIV infection, the sphingomyelins and phospholipids correlated 
negatively to markers of infection IP-10 and sIL-2R whereas a strong association was found between 
triglycerides and MCP-1. In a second cohort, we characterized plasma samples obtained from 28 HIV-
1-infected adult patients before and 12 months after the start of cART, to investigate the immune-
metabolic changes associated with cART. The identified altered immune-metabolic pathways of an 
untreated HIV infection showed minimal change after 12 months of cART. In conclusion, 12 months of 
cART impacts only mildly on the metabolic dysregulation underlying an untreated HIV infection and 
provide insights into the comorbidities present in virally suppressed HIV patients.
The interaction of the Human immunodeficiency virus (HIV) with its host is a complex process with a grow-
ing body of literature revealing the capacity of HIV to induce a plethora of metabolic changes in the human 
body1–5. Hypertriglyceridemia was identified as one of the first metabolic consequences of HIV infection6. Since 
then, studies using Mass Spectrometry (MS) and Nuclear Magnetic Resonance (NMR) applied to biofluids of 
HIV-infected individuals have confirmed the presence of HIV induced metabolic alterations1,7–9. Investigating 
in vitro models of HIV infection using primary macrophages and CD4+ T-cells had different metabolic out-
comes during HIV infection. CD4+ T-cells infected with HIV exhibited increased glucose uptake and upregu-
lated glycolytic intermediates compared to reduced glucose uptake and steady-state glycolytic intermediates in 
HIV-infected macrophages10. While, in vivo models using rhesus macaques infected with simian immunode-
ficiency virus (SIV) revealed increased fatty acids, phospholipids, and acyl-carnitines, suggesting an impaired 
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mitochondrial fatty acid oxidation11. Comparatively, serum and plasma derived from HIV infected individu-
als revealed altered metabolites of lipid and mitochondrial pathways as well as organic acids and fatty acids1,5. 
Moreover, the saliva from HIV-infected patients versus healthy controls revealed alterations in carbohydrate 
biosynthesis and degradation2.
Infection with HIV causes a progressive malfunctioning of the human immune system. HIV infection depletes 
CD4+ T-cells, while also inducing functionally exhausted CD8+ T-cells and impaired NK cells, leaving the host 
vulnerable to opportunistic infections12. Furthermore, the metabolic and immunological changes in untreated 
HIV patients increase the risk of developing comorbidities, including cardiovascular disease (CVD), insulin 
resistance and HIV-associated neurocognitive disorders (HAND)13,14.
The advent of combination antiretroviral therapy (cART) provided an important lifeline for HIV patients, 
since cART effectively inhibits HIV replication to undetectable levels, while also enabling the restoration of the 
immune system with increasing CD4+ T-cell counts. Nevertheless, important metabolic-related side-effects of 
cART are reported in patient populations, mainly lipodystrophy and insulin resistance, which may further pre-
dispose virally suppressed patients to increased CVD, diabetes, and kidney damage15–17. Also, studies have shown 
that although cART dramatically decreased the incidence of the most severe clinical phenotype of HAND (HIV 
associated neurocognitive disorder) – HIV-associated dementia - in virally suppressed patients the milder forms 
of HAND - asymptomatic neurocognitive impairment and mild neurocognitive disorders- have become more 
prevalent18,19. One aspect of the pathogenesis of CVD or HAND in successfully treated HIV patients is that while 
cART effectively suppresses HIV replication and activity, low levels of immune activation are sustained20–22. The 
ability of cART to rectify the HIV-induced metabolic dysregulation is unclear and under-investigated. However, 
this may be highly relevant since persistent metabolic stress could be an underlying pathogenic mechanism in 
the comorbidities of untreated HIV patients as well as cART suppressed HIV patients. Robust characterization of 
the metabolic alterations experienced during HIV infection is needed to determine the effect of cART on these 
pathways, in cART suppressed HIV patients.
To study this, we used comprehensive targeted metabolomics techniques integrated with classical immu-
nological assays and compared changes in plasma of untreated HIV-1 patients to non-HIV infected individu-
als, and paired plasma of untreated HIV-1 patients at baseline to their plasma after 12 months of cART in the 
HIV-suppressed state, to assess whether profiles normalized to the situation in healthy individuals or remained 
perturbed. We found dysregulated biogenic amine and lipid metabolism in untreated HIV-infected patients, con-
ditions that have been independently associated with the pathophysiology of CVD and HAND. After 12 months 
of cART, metabolic changes were found for some biogenic amines, while the lipid metabolites revealed increasing 
levels in the virally suppressed patients.
Results
Untreated HIV versus non-HIV-infected controls. Patient population A. Most of the individuals in 
both the patient and the control populations listed in Table 1 were male and Caucasians. Mean age did not differ 
between both groups. The mean CD4+ T-cell count of the HIV-1 patients was 441 × 106 cells/L with an interquar-
tile range (IQR) of 367.5 × 106. The untreated HIV patients had a large heterogeneity in viral load with a median 
of 1.11 × 105 viral copies and an IQR of 2.64 × 105 especially when taking the minimum and maximum values as 
listed in Table 1 into account.
Altered plasma metabolic profiles in untreated HIV-infected patients. To characterized metabolic alterations 
experienced during an untreated HIV-1 infection, we compared 18 untreated HIV-1-infected patients (popu-
lation A) with 23 controls through profiling their biogenic amines, lipids, and signalling lipid metabolites. As 
shown in the volcano plot in Fig. 1a, 18 biogenic amines were differently affected in HIV patients versus con-
trols, with reduced levels in all (see Supplementary Table S1). Reduced levels of antioxidants, including total 
glutathione and taurine, together with lipid headgroup moieties o-phosphoethanolamine and the choline metab-
olite sarcosine were identified as the most significantly altered amine metabolites during an untreated HIV 
infection. Furthermore, untreated HIV patients had decreased levels of tryptophan and serotonin compared to 
controls. The plasma kynurenine/tryptophan (K/T) ratio, as a readout for indoleamine 2,3-dioxygenase (IDO) 
activity, showed upregulated IDO activity during untreated HIV infection compared to controls (p = 0.0003) 
(see Supplementary Fig. S1A). Concurrently investigating the plasma serotonin/tryptophan ratio reflected the 
consequences of increased IDO activity for serotonin synthesis during untreated HIV infection compared to 
controls (p < 0.0001) (see Supplementary Fig. S1B). Decreased levels of the branch chain amino acids leucine 
and isoleucine as well as carnosine reflected impaired muscle metabolism during an untreated HIV infection. 
The significantly decreased levels of ornithine and putrescine in untreated HIV patients also hints at a reduced 
Characteristics Patients (n = 18)
Controls 
(n = 23) P-value
Age; mean (±SD; years) 40 (10) 36 (10) 0.18
Male Gender (n/%) 16 (88.9%) 14 (60.9%) 0.08
Caucasian (n/%) 14 (77.8) 17 (73.9%) 0.90
CD4+ T-cell count; mean (±SD; x106/L) 441 (265) — —
HIV viral load; median (min-max; copies/mL) 1.1 × 105 (60–1 × 107) — —
Table 1. Characteristics of the untreated HIV-infected patients (Population A) and the non-HIV infected 
control population.
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urea cycle and thus ammonia clearance in these patients compared to controls. Additionally, decreased levels of 
alanine, asparagine, α-aminobutyric acid, tyrosine, and methionine were also detected in untreated HIV patients 
compared to controls. Evaluation of the levels of plasma lipids, which included the different lysophospholipids 
classes, phospholipids, di/triglycerides, sphingomyelins, ceramides, and cholesterol esters, revealed 44 modulated 
metabolites with a p < 0.05 and a fold-change (FC) ≥ 1.30 or ≤0.70 (Fig. 1b and Supplementary Table S2). The 
lysophospholipids class presented with 6 lysophosphatidic acid (LPA) species having increased plasma levels in 
untreated HIV-infected patients versus controls, and one lysophosphatidylcholine (LPC) metabolite which was 
reduced compared to controls. Furthermore, two monounsaturated sphingomyelin (SM) species, two PUFA cho-
lesterol ester (CE), and two long-chain saturated ceramides (CER) metabolites all had reduced levels in untreated 
Figure 1. Plasma metabolic characterization of untreated HIV vs controls. Volcano plot of (a) the biogenic 
amine profile. (b) The lipid profile. (c) The signalling lipid profile. Volcano plots are representative of the −
log10(Mann-Whitney p-value) on the y-axis with the x-axis showing the log2(Fold change) of the metabolite, 
between the controls and the untreated HIV patients (population A) respectively. Dashed lines represent 
the respective significance thresholds, with the significant metabolites identifiable by coloured symbols with 
either a name or corresponding class colour identifier. CE – Cholesterol esters; CER – Ceramides; PC – 
Phosphatidylcholines; PC-O - Plasmalogen PCs; PE – Phosphatidylethanolamines; PE-O – Plasmalogens PEs; 
SM - Sphingomyelins; TG - Triglycerides; LPA – Lysophosphatidic acid; COX - Cyclooxygenase; CYP450 – 
Cytochrome P450; LOX - Lipoxygenase; RNS – Reactive nitrogen species; ROS – Reactive oxygen species.
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HIV patients. The triglycerides (TG) profile presented with 14 mostly polyunsaturated triglycerides species show-
ing significantly increased levels during untreated HIV infection. The phospholipids presented with seven phos-
phatidylcholines (PC), four plasmalogen phosphatidylcholines (PC-O), two phosphatidylethanolamines (PE) and 
two plasmalogen phosphatidylethanolamines (PE-O) all having decreased levels during untreated HIV.
The third subclass of metabolites that were evaluated for differences between untreated HIV patients and 
controls was the class of signalling lipid mediators, derived from the enzymatic or free radical oxidised pol-
yunsaturated fatty acids, which includes the prostaglandins, thromboxanes, hydroxy-fatty acids, leukotrienes, 
resolvins, epoxy-fatty acids, isoprostanes and nitro fatty acids. During the untreated HIV infection 22 signifi-
cantly affected signalling lipid metabolites were identified of which 8 had reduced levels and 14 had increased 
levels in the untreated HIV patients compared to controls. (Fig. 1c, Supplementary Table S3). The four signalling 
mediators: 5,6-DiHETrE, 8,9-DiHETrE, 11,12-DiHETrE, and 14,15-DiHETrE all derived from arachidonic acid 
and synthesised by cytochrome P450 isozymes showed the most significant increased levels in the untreated 
HIV patients compared to the controls. Furthermore, untreated HIV patients had increased levels of dihydro-
sphingosine but decreased levels of three different Sphingosine-1-phosphate species compared to controls. The 
metabolites 5-HETE, 12-HETE and 15-HETE derived from the Lipoxygenase activity on Arachidonic acid, also 
had increased levels compared to the controls. Oxidized lipids due to the activity of ROS and RNS showed dif-
ferential responses with increased levels of 8-iso-PGE2, 2,3-dinor-PGF2a and 20 HETE and decreased levels of 
11-HDoHE and 8,12-iPF2α-IV in untreated HIV patients compared to controls.
Untreated HIV versus HIV-suppressed (12 months of cART). Patient population B. The character-
istics of the HIV-1-infected patients selected to compare baseline metabolic profile to the HIV-suppressed profile 
after 12 months of therapy (population B) are presented in Table 2. This is an independent population from the 
untreated HIV-infected population A introduced in Table 1. Most of the patients had a male gender. Mean CD4+ 
T-cell count at the start of cART was of 267 × 106 cells/L with an IQR of 224 × 106. There was a large hetero-
genicity in viral load with a median of 5.5 × 104 copies/ml and an IQR of 2.7 × 105. 89% of the patients were of 
European descent. Four patients had a blip in their viral load at 12 months on cART: their viral loads were 53, 73, 
103 and 130 copies/ml. Most patients used Abacavir in combination with Lamivudine as the backbone in cART 
(n = 25). The patients who only used NRTI’s all used the combination Abacavir with Lamivudine and Zidovudine 
(n = 8) except for one patient who used Abacavir/Lamivudine with Stavudine. The protease inhibitors (PI) used 
were Lopinavir (in combination with ritonavir) (n = 4), Atazanavir (n = 1) and Darunavir (n = 1). The NNRTI’s 
used were Efavirenz (n = 8), Nevirapine (n = 4) and Rilpivirine (n = 1). Five patients used a statin. The incidence 
of dyslipidaemia or the use of lipid-lowering therapy (statins and/or fibrates) remained stable during the first year 
of cART.
Metabolic consequences following cART treatment of HIV patients. Next, we evaluated the metabolic changes 
associated with 12 months of cART treatment, as well as HIV suppression in the longitudinal patient population 
B. cART treatment of the HIV patients resulted in viral suppression with undetectable plasma HIV RNA levels 
and partial restoration of CD4+ T-cell counts in the blood (Table 2). Eight HIV infected patients were HCV 
positive, but were untreated for HCV during the 12-month period and were not excluded from the analyses. The 
untreated HCV infection had minimal impact on the metabolic findings as can be seen in see Supplementary 
Fig. S2. Evaluation of biogenic amine levels in paired plasma samples showed significantly increased methio-
nine sulfone, histidine and tryptophan levels during the therapy period as compared to the baseline samples 
(untreated HIV), whereas pipecolic acid, 3-aminoisobutyric acid, and kynurenine showed significantly decreased 
levels during the therapy period as compared to the baseline (Fig. 2a, Supplementary Table S4). Significant metab-
olites were identified by having a false discovery rate adjusted p-value < 0.05 using a paired t-test approach. The 
K/T ratio revealed significantly decreased IDO activation after 12 months of cART (see Supplementary Fig. S3), 
however, the ratio between tryptophan and serotonin showed no significant changes. The neurotransmitter dopa-
mine and metabolite α-aminobutyric acid correlated with CD4+ T-cell counts during 12 months of therapy (see 
Supplementary Fig. S4A).
The lipid profile showed an overall increasing trend reflecting higher levels after the 12-month cART period 
compared to their baseline levels, as can be seen in Fig. 2b. Predominantly it was the phosphatidylcholine metab-
olism responding to cART with significantly increased levels of 9 phosphatidylcholine species, 8 plasmalogen 
phosphatidylcholine, and 3 lysophosphatidylcholine species after 12 months of cART compared to baseline values 
prior to starting of cART. Furthermore, 7 sphingomyelin metabolites, together with one phosphatidylethanola-
mine species, two plasmalogen phosphatidylethanolamine, and a cholesterol ester were also increased after 12 
months of cART compared to their baseline values. Furthermore, the phosphatidylcholines also revealed a posi-
tive association with CD4+ T-cell counts of the patients (see Supplementary Fig. S4B).
Finally, we compared changes in the signalling lipid profiles in patient plasma after 12 months of cART to their 
untreated HIV levels and found no significant changes.
Plasma immune-metabolic networks of HIV infection and therapy. Plasma levels of cytokines and 
immune mediators are a commonly used readout reflecting systemic immune activity23,24. To correlate metabolite 
profiles in plasma with immune activity, we determined in subsequent plasma samples of the same patients the 
levels of the infection markers IP-10, sIL-2R, and D-dimer, the inflammation markers IL-6, IL-10, IL-21, IL-18, 
and MCP-1, and the soluble exhaustion markers sPD1, sPD-L1, sPD-L2, and sTIM3. Significantly enhanced 
plasma levels of D-Dimer, IL-18, MCP-1, sPD-L2, sTim-3, IP-10, sIL-2R, CRP, and sTNF-RII were observed 
in patients with untreated HIV as compared to non-HIV infected controls (Population A), and are shown in 
Supplementary Fig. S5. The other mediators tested were below the limit of detection of the assay, which included 
IL-6, IL-10, IL-21, sPD1, and sPD-L1.
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Evaluating the changes in the immunological parameters in population B after the 12 months cART period 
revealed an immunological picture of effective therapy shown in Supplementary Fig. S6. Markers of infec-
tion revealed that after the initiation of cART, both plasma IP-10 and sIL-2R levels were reduced significantly. 
Furthermore, initiation of cART reduced the levels of the inflammation marker IL-18 whereas MCP-1 levels 
remained unchanged when comparing baseline to 12 months of cART. An improvement in markers of exhaustion 
was found with reducing levels of both sPD-L2 and sTIM3 after 12 months of cART.
Next, we constructed immune-metabolic correlation networks respectively for the controls and the patients 
with an untreated HIV infection from population B using the absolute of levels of metabolites and immune 
mediators. Figure 3 presents these three immune-metabolic correlation networks showing all correlations with a 
strict p-value cut-off of p < 0.01. Comparing Fig. 3a (the control network) to Fig. 3b (the untreated HIV network) 
difference is seen in the interactions between the two networks. The control network revealed isolated clusters 
with IP-10 and IL-18 correlating to different lipid classes, sIL-2R and sTNF-RII correlated together and D-Dimer, 
sTIM3 and MCP-1 showing correlation. Comparatively the untreated HIV shows positive correlations between 
sTIM-3, sIL-2R, IP-10 and sPD-L2 with D-Dimer connecting the network through sTIM-3, revealing correla-
tions between markers of infection and exhaustion. In both networks, sTIM-3 and D-Dimer revealed strong 
positive correlations, while in the untreated HIV patients sTIM-2 also showed strong interactions with phospho-
lipids as well as lysophospholipids. Furthermore, in untreated HIV patients MCP-1 correlated strongly to several 
triglyceride species compared to the control network where MCP-1 correlate only to D-Dimer. Interestingly, in 
the control network, IL-18 showed strong interactions with triglyceride species, whereas IL-18 was correlated to 
only 5,6-DiHETrE in the untreated HIV patients.
Next, for the influence of cART on HIV infection, we constructed immune-metabolic correlation network 
based on the relative change in levels of metabolites and immune mediators in the paired plasma of the patients 
on 12 months cART versus their untreated HIV levels. As shown in Fig. 3c, the correlation network revealed 
distinct immune-metabolic interactions. Firstly, changes in sTIM-3, sIL-2R, IP-10, sPD-L2 and IL-18 positively 
correlated with each other, with D-dimer becoming disconnected from the core network. Again, MCP-1 showed 
minimal interactions to other immune mediators in the panel: changes in triglyceride levels correlated strongly to 
changes in MCP-1 levels as did some amine metabolites, while changes in two cholesterol-esters showed negative 
correlations. Furthermore, cART diminished the interaction of sTIM-3 with the phospholipids and lysophospho-
lipids which were found in untreated HIV-patients.
Characteristics At baselinea ±12 months of cART
Age; mean (±SD; years) 40 (10)
Male Gender (n/%) 21 (75.0%)
European region of origin (n/%) 25 (89.3%)
Statin use (n/%) 4 (14.3%) 5 (17.9%)
Mean Cholesterolb > 6.5c (n/%) unknown 6 (21.4%)
Mean LDL > 4.5c (n/%) unknown 4 (14.2%)
Mean Triglycerides > 2.3c (n/%) unknown 8 (28.6%)
BMId; mean (±SD; kg/m2) 22.7 (3.1) 23.1 (3.3)
Hepatitis B coinfection (n/%) 1 (3.6%)
Hepatitis C coinfection (n/%) 8 (28.6%)
Alcohol ≥ 5 IE/day (n/%) 1 (3.6%)
Hard drugse or methadone use (n/%) 8 (28.6%)
CD4+ T-cell countf mean (±SD; x106/L) 267.4 (158.9) 489.0 (209.4)
Time on cART; mean (±SD; months) n.a. 12.5 (1.2)
HIV viral load < 102 g (n/%) 0 (0%) 26 (93.6%)
HIV viral load > 102 g (n/%) 28 (100%) 2 (7.2%)
HIV viral loadg; median (min-max) 5.5 × 10
4 (1.6 × 103 – 
8.1 × 105)
cART regimen NRTIh + NNRTIi (n/%) n.a. 13 (46.4%)k
cART regimen NRTIh + PIj (n/%) n.a. 6 (21.4%)k
cART regimen NRTIh only (n/%) n.a. 9 (32.1%)k
Table 2. Characteristics of 28 HIV-infected patients (Population B) at baseline and after 12 months of cART. 
acART = combination Anti-retroviral therapy; bmean value of 6 months prior to sample used; cmmol/L; 
dBMI = Body mass index; ecocaine, heroin and/or MDMA (3,4-methylenedioxymethamphetamine); fx106/L; 
gcopies/ml; hNRTI = Nucleoside reverse transcriptase inhibitor; iNNRTI = Non-nucleoside reverse transcriptase 
jPI = Protease inhibitor; kThree patients used a different cART regimen at 6 months versus 12 months of cART. 
Because of one patient switching from a protease inhibitor (PI) based regimen to a non-nucleoside reverse 
transcriptase inhibitor (NNRTI) or nucleoside reverse transcriptase inhibitor (NRTI) only regimen and vice 
versa, the proportion of PI-based, NNRTI based or NRTI the only regimen remained unchanged in the entire 
group.
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Discussion
The data presented in this study provide some insight into the distinct effects of HIV and cART have on metab-
olism. Through identifying immune-metabolic pathways altered during untreated HIV infection, we can fol-
low these pathways during the first 12 months after commencing cART in the same patients, monitoring their 
responses. In line with earlier research, we found decreased glutathione, taurine and tryptophan levels as well as 
upregulated IDO activity in untreated HIV patients compared to HIV-seronegative controls8,25,26. Also, increased 
levels of highly unsaturated long-chain triglycerides27 and decreased levels of sphingomyelin species character-
ized an untreated HIV Infection compared to controls. After the initiation of cART, changes in the lipid metab-
olism were primarily found within the phospholipids while the highly unsaturated triglyceride species remained 
elevated. A noteworthy metabolic finding is the unresponsive signalling lipid profile, showing minimal changes 
after the first 12-month cART period. Signalling lipids including eicosanoids are metabolically derived immu-
nological mediators and might represent a metabolic reflection of the immune competence of HIV-infected 
patients28,29. The unresponsive signalling lipid metabolism could result from the sequestering of their polyun-
saturated fatty acid precursors into triglyceride species. Cassol et al. reported decreased eicosanoid levels spe-
cifically 5-hydroxyeicosatetraenoic acid (5-HETE), prostaglandin B2, prostaglandin E2 and thromboxane B2 in 
cART-treated HIV-positive individuals compared to controls1. Since eicosanoids also play an essential role in 
immunological crosstalk30 it could help to explain the dysregulated immune surveillance and exhausted pheno-
type persisting in virally suppressed patients31.
Studying the immune-metabolic networks revealed that the initiation of cART disconnected the interactions 
between kynurenine and sIL-2R as well as sTIM-3’s interactions with phospholipids and lysophospholipids. Thus, 
HIV suppression through cART attenuates the pro-inflammatory sIL-2R and IDO pathways differently, since it 
has been reported that IDO activity remains significantly increased compared to controls even after 24 months 
of cART32. Secondly, cART might contribute to an exhausted immune phenotype through dysregulating the 
phospholipids (increased during the first 12 months of cART) and their interactions with sTIM-3 interactions. 
Figure 2. Plasma metabolic characterization of response to 12 months’ cART. Modified volcano plots 
showing (a) the biogenic amine profile, and (b) the lipid profile. The modified volcano plots are representative 
of the −log10(FDR adjusted paired t-test p-value) on the y-axis with the x-axis showing the scaled mean of 
the paired differences per metabolite, between the baseline and 12 months cART follow-up sample (patient 
population B). The horizontal dashed line represents a false discovery rate adjusted q-value < 0.05. Significant 
metabolites are identifiable by coloured symbols with either a name or corresponding class colour identifier. CE 
– Cholesterol esters; LPC – Lysophosphatidylcholines; PC – Phosphatidylcholines; PC-O - Plasmalogen PCs; PE 
– Phosphatidylethanolamines; PE-O – Plasmalogens PEs; SM – Sphingomyelins.
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Further, IL-18, a pro-inflammatory cytokine found elevated in advanced stages of HIV infection33, showed 
strong correlations to triglyceride levels in the control population. The role of IL-18 in cardiovascular disease 
and the metabolic syndrome, as well as its association with triglyceride levels, has been previously described34,35. 
Comparatively, in the untreated HIV infected population, the triglyceride species showed a strong correlation 
to MCP-1 levels and not to IL-18. Initiating 12 months of cART was unable to nullify this interaction, reveal-
ing that changes in triglyceride levels still strongly correlated to those of MCP-1 in the paired patient samples. 
Mihăilescu et al., found that the prevalence of insulin resistance and metabolic syndrome was higher in HIV 
suppressed patients compared to virally active patients, and that the levels of MCP-1 correlated to both these 
co-morbidities36, supporting our findings.
Disentangling the mechanism behind the observed metabolic changes during an HIV infection and ther-
apy is a complex task. However, the importance of this task is stressed by the findings in this study that even 
12 months of cART does not attenuate metabolic dysregulation. This is opposed to the finding that immune 
activation in HIV-infected patients is normalized during treatment with cART for this same period, as we also 
previously showed33. Sustained immune activation thus is not the complete answer to what causes co-morbidity 
in HIV-infected patients, like neurocognitive disorders and cardiovascular disease. Although cART has become 
increasingly effective over the last years, but as we show here, is not enough to fully restore the metabolic profile 
of HIV-suppressed patients to normal.
This finding warrants further research, to contribute to unravelling the metabolic pathophysiological path-
ways in HIV comorbidities, with multiple findings in this study able to generate testable hypothesis regarding 
HAND and CVD. With respect to HAND, the following questions arise applicable to both untreated HIV and 
cART-treated HIV patients. (1) How does the sustained elevated Indoleamine-2,3-dioxygenase (IDO) activity 
(the rate-limiting enzyme catabolizing L-tryptophan into neurotoxic metabolites and not serotonin) contribute to 
Figure 3. Immune-metabolic networks of controls, untreated HIV and the influence of cART. (a) Control 
immune-metabolic correlation network based on correlating the absolute levels of plasma metabolites and 
plasma cytokines in the control group. (b) Untreated HIV immune-metabolic correlation network based 
on correlating the absolute levels of plasma metabolites and plasma cytokines in the untreated HIV group 
(Population B). (c) The immune-metabolic correlation network following 12 months cART. Using the paired 
samples of population B, the relative change in levels of 12 months’ cART compared to their baseline levels 
(untreated HIV sample) were determined for plasma metabolites and cytokines and subsequently correlated. 
For all three networks, spearman correlations were performed and significant correlations were defined as 
having a strict p-value (two-tailed) < 0.01.
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neurological disorders? (2) What is the pathological mechanism underlying a dysregulated urea cycle during an 
untreated HIV infection? Since disorders of the urea cycle are known to manifest with neurological implications 
due to hyperammonemia37. Similarly to HAND, questions relating to CVD, an important cause of morbidity 
and mortality in untreated and suppressed HIV-infected patients, arises38,39. (3) Do the significant correlations 
between changes in triglycerides and MCP-1 levels, expose an alternative mechanism contributing to the develop-
ment of CVD, independent of IL-18? (4) How does an unresponsive eicosanoid metabolism contribute to CVD, 
since they play an important role in normal cardiovascular function?40–42. Potentially with the answer to these 
questions, morbidity, and mortality in HIV-infected patients because of the non-communicable disease can be 
further diminished.
It is important to note that in our study the time of follow-up of these patients was too short to draw conclu-
sions about causality. The use of targeted metabolomics platforms in conjunction with other omics technologies 
would provide a unique opportunity to study HIV pathogenic mechanisms, as well as to identify biomarkers 
relevant to co-morbidities relating to both HIV and the use of ARVs. Studies investigating the metabolic dys-
regulation of HIV infections and exposure of antiretrovirals can be further strengthened by investigating paired 
longitudinal samples with a known outcome. Furthermore, these techniques could also proof complementary to 
antiretrovirals pharmacokinetic studies currently in clinical trials.
It is important to mention that due to the retrospective nature of the part of our study in which we compared 
cART naïve HIV-infected patients with their samples after 12 months of therapy, it is difficult to ascertain whether 
all blood samples were processed identically, thereby introducing some variation in outcome parameters. Further, 
the duration of the HIV infection prior to starting cART is not known of these patients. Apart from the HIV 
infection, other factors might play a role in metabolic changes, for instance, smoking habits, aging, and timing 
of sampling of the material. Also, we have no data on the fasting state of both the patient as well as the control 
population, however, because the samples of the included patients were taken during routine outpatient visits 
and blood donors, in general, are instructed not to donate blood in the fasted state, it is safe to assume that both 
groups were in a post-prandial state. Food intake can affect metabolites and phospholipid levels43,44, but also mul-
tiple large population studies have shown that changes in plasma lipids and lipoproteins change only modestly 
during the day, in response to habitual food intake45,46. Further, although sub-analysis of 12 months cART accord-
ing to PI or NNRTI used did not show differences in lipid profiles, the choice of the specific components of the 
cART regimen might be a significant factor or influence on the metabolic profile of a patient in the long run. 
For instance, abacavir use, which is associated in the literature with an increase of CVD47,48. Population A and B 
differed significantly from each other regarding mean CD4+ T-cell counts and cytokine profiles, probably due 
to the fact that Population A was selected to be compared to a non-HIV infected, healthy control population and 
therefor selection criteria was more strictly defined than those for population B, where the patients were their 
own controls. In population B, five patients were using statins during the first year of cART, of which four were 
already receiving statin therapy prior to the start of cART. We were unable to identify any trends in the data indi-
cating that lipid profiles were skewed based on the use of statins. Eight patients were coinfected with HCV, which 
may have had an effect on the comparison of the untreated patients compared to controls. However, during this 
study, none of the patients was treated for HCV, thus this was a stable factor in the comparison between untreated 
HIV and 12 months of cART. A sub-analysis leaving out the HCV coinfected patients showed minimal impact on 
the outcome. In this study, we were not able to include a sample of the control patients after one year. However, 
to determine the baseline stability of the metabolic/immune network, further studies are needed with follow-up 
samples of a control population.
In conclusion, in our study, we found significant changes in the metabolism relevant of untreated HIV infected 
patients and after 12 months cART. Additional to this finding, and potentially even more important is the finding 
that cART alone does not restore these changes. Further insight into the metabolic changes caused by HIV infec-
tion is warranted to optimize therapy in addition to cART for this patient population.
Methods
Patients and sample collection. Untreated HIV versus non-HIV-infected controls, population A. For the 
comparison of metabolic profiles of untreated HIV-1-infected patients to a non-HIV infected control population, 
18 HIV-1-infected, cART naïve patients were selected from the outpatient clinic of the Erasmus Medical Center 
in Rotterdam, The Netherlands, archived sample bank. The plasma was stored at −80 °C. Inclusion criteria were 
age over 18 years and no previous treatment for HIV. Exclusion criteria were severe comorbidity (e.g. diabetes 
mellitus, cardiovascular disease, opportunistic infection), coinfection with hepatitis B or C, use of alcohol > 2 
IU/day and use of co-medication. All patients had given written informed consent for inclusion in the database 
of the Dutch HIV monitoring foundation (Stichting HIV Monitoring; SHM) also known as the AIDS Therapy 
Evaluation in the Netherlands (ATHENA) cohort, and collection of demographic, laboratory and clinical data 
from the medical records and storage and future use for scientific research of biological material. Their plasma 
samples were compared to a non-HIV infected control population from volunteers (n = 23), without comorbidity 
or co-medication, which had all given their written informed consent.
Untreated HIV versus HIV-suppressed (12 months of cART), population B. For the comparison of metabolic pro-
files of untreated HIV-1-infected patients to the HIV-suppressed situation, plasma samples of 28 HIV-1-infected 
patients from the outpatient clinic of the Maastricht University Medical Center in Maastricht, The Netherlands 
were selected in the archived sample bank. The plasma was stored at −80 °C. All patients had given written 
informed consent for inclusion in the database of the Dutch HIV monitoring foundation and collection of demo-
graphic, laboratory and clinical data from the medical records and storage and future use for scientific research 
of biological material. From each included patient, a plasma sample was selected from before the start of cART 
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and at 12 months after the start of cART. All patients were older than 18 years at the start of cART and had not 
received any previous ART therapy. All patients started with a cART regimen containing Abacavir. The patients 
had no diabetes mellitus and no diagnosed autoimmune diseases. We retrieved information regarding dyslipidae-
mia from the earlier laboratory results prior to the 12 months samples after the start of cART. Because the patients 
were generally not in care prior to the HIV diagnosis, no values were available from the blood sample prior to 
the start of cART. The study was performed according to the Helsinki Declaration and approved by the Ethical 
Committee of the Maastricht University Medical Center.
Targeted LC-MS metabolomics. Targeted metabolomics analyses were performed using standard operat-
ing procedures derived from previously published methods49–52. Detailed procedures and target lists are provided 
in the Additional file 1 - Methods with a brief overview of the four platforms used given in Table 3. After LC-MS 
analyses, peak integration was done using the instrumental software, and the relative ratios between metabolites 
and their corresponding internal standards were determined.
Metabolomics quality controls. Quality control (QC) samples consisted of equal aliquots of a QC pool made by 
combining equal volumes (±25 µL) of all study samples. A set of QC samples was then included during the anal-
yses of the experimental groups on the individual metabolomic platforms and evenly distributed across the ran-
domized samples prior to LC-MS analyses. In addition, independent duplicate samples (10–15%) were randomly 
selected. Using the QC samples and duplicate samples, a double-QC approach was applied to include metabolites 
that were reliably measured by the individual metabolomics platforms by reporting and using only those metab-
olites for which both duplicate samples and QC samples showed an RSD < 30%.
Multiplex immunoassays to assess plasma biomarkers. The levels of cytokines, chemokines, 
growth factors and other proteins were determined using the Procarta Plex human Immune Monitoring Panel 
(Affymetrix, Vienna, Austria). The panel measured 14 proteins simultaneously and consisted of IP-10, IL-10, 
IL-6, D-dimer, sIL-2R, IL-21, IL-18, MCP-1, sPD-L1, sPD-L2, sTIM3, sPD1, CRP, and sTNF-RII. The assay was 
conducted according to the manufacturer’s instructions, identical to the procedures used in our previous stud-
ies53–55. The concentrations of analytes were measured using the microsphere-based multiplex Luminex-100 
(Luminex Corporation, Austin, TX, USA), Samples to compare untreated HIV with non-HIV controls were ana-
lyzed in a different run than paired samples of untreated and HIV-suppressed patients. Data were analyzed using 
ProcartaPlexAnalyst 1.0 (www.ebioscience.com/resources/procartaplex-analyst-1.0-software.htm).
Statistical analyses. SPSS 21.0 (SPSS Inc., Chicago, IL, USA) was used for Fisher’s exact tests on the 
patient cohort characteristics presented as frequencies, and ANOVA on the continuous values. A combination 
of univariate and multivariate bioinformatics approaches was performed using the R script‒based online tool 
Metaboanalyst 3.0, a comprehensive tool suitable for analysing metabolomics data56. The metabolomics datasets 
were log transformed and auto-scaled prior to bioinformatics analyses. For the analyses between controls and 
untreated HIV patients, significant metabolites were identified per metabolomics platform based on the following 
criteria: i. a p-value < 0.05 using the unpaired student t-test, and ii. a fold change (FC) ≥ 1.30 or ≤0.70, indicat-
ing a 30% increase or decrease. The False discovery rate’s q-values are reported for every reported p-value. For 
the analyses between the paired untreated HIV patients and 12 months cART follow up, significant metabolites 






























Positive lipid49 10 μL Isopropyl alcohol extraction UPLC-QToF
Lysophospholipids, 
phospholipids, cholesterol 
esters, di/triglycerides & 
sphingomyelins
250 147 0.02%
Oxylipins51 250 μL Oasis HLB SPE extraction HPLC-MS/MS
Hydroxylated fatty 
acids, prostaglandins & 
thromboxanes
120 68 7.7%













& lysophosphatidic acids 
species.
Table 3. Metabolomics platforms. A brief overview of the platforms detailing volumes, sample preparation, 
and analytical instruments. UPLC – Ultra Pressure Liquid-Chromatography; TQMS – Triple quadrupole mass 
spectrometer; QToF – Quad Time of Flight; HPLC - High-Pressure Liquid-Chromatography; UHPLC – Ultra 
High-Pressure Liquid-Chromatography; MS/MS – Triple quadrupole Mass Spectrometer.
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student t-test. Plasma protein biomarkers were analysed using the unpaired student t-test for comparing controls 
and untreated HIV patients, and the paired student t-tests across the paired patients’ samples at baseline and 12 
months. GraphPad Prism 7 software was used in the rendering of graphs and figures.
Two types of immune-metabolic correlation networks were done. Firstly, for the control group and the 
untreated HIV patient group, independent Spearman correlation analyses were done using the absolute metab-
olite and cytokine levels. Next, per group cytokine levels were correlated with each other to form the network 
skeleton. The second type of correlation network was based on Spearman correlations of the levels of metab-
olites to cytokines in HIV-suppressed patients after 12 months of cART relative to the levels at baseline from 
paired patient samples (relative change = 12 months cART – baseline). Next, we correlated the relative change 
in cytokine levels to form the network skeleton. For both types of immune-metabolic correlations significant 
correlations were defined using a cut-off p-value (two-tailed) < 0.01 and were visualized as a network using the 
Metscape application within Cytoscape (v3.4.0).
Ethics approval and consent to participate. This study was conducted in accordance with the guidelines 
of the Declaration of Helsinki and the principles of Good Clinical Practice. The ethical review board of the Erasmus 
MC has approved the study, and informed consent was obtained from all patients who were asked to donate blood.
Availability of Data and Material
The metabolomics datasets supporting the conclusions of this article will be made available in the online Metab-
oLights data repository.
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